Long COVID Patterns in the RECOVER-Adult Study
November 21, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
viberzi
Synonyms :
Eluxadoline
Class :
Mu-receptor agonists, IBS agents
Brand Name :
viberzi
Synonyms :
Eluxadoline
Class :
Mu-receptor agonists, IBS agents
Dosage Forms & StrengthsÂ
TabletÂ
75mgÂ
100mgÂ
Irritable Bowel Syndrome (IBS)Â
100
mg
Tablet
Orally 
Twice a day after meal
may enhance the serum concentration of BCRP/ABCG2 inhibitors
may enhance the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) inhibitors
may enhance the serum concentration of BCRP/ABCG2 inhibitors
may enhance the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) inhibitors
may enhance the serum concentration
may enhance the serum concentration
may enhance the serum concentration
may enhance the serum concentration
may enhance the serum concentration
eluxadoline: they may increase the CNS depressant effect of CNS Depressants
eluxadoline: they may increase the CNS depressant effect of CNS Depressants
eluxadoline: they may increase the CNS depressant effect of CNS Depressants
eluxadoline: they may increase the CNS depressant effect of CNS Depressants
eluxadoline: they may increase the CNS depressant effect of CNS Depressants
eluxadoline: they may increase the bradycardic effect of Bradycardia-Causing Agents
eluxadoline: they may increase the bradycardic effect of Bradycardia-Causing Agents
eluxadoline: they may increase the bradycardic effect of Bradycardia-Causing Agents
eluxadoline: they may increase the bradycardic effect of Bradycardia-Causing Agents
eluxadoline: they may increase the bradycardic effect of Bradycardia-Causing Agents
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may enhance the serum concentration of OATP1/1B3 substrates
acrivastine and pseudoephedrineÂ
may increase the constipating effect of anticholinergic agents
may enhance the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors
may enhance the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors
may have an increased Effect of CNS depressant when combined with opioid agonists
may have an increased Effect of CNS depressant when combined with opioid agonists
may have an increased Effect of CNS depressant when combined with opioid agonists
may have an increased effect of a CNS depressant when combined with opioid agonists
may have an increased effect of a CNS depressant when combined with opioid agonists
may have an increased effect of a CNS depressant when combined with opioid agonists
anticholinergic agents increase the effect of constipation of eluxadoline
anticholinergic agents increase the effect of constipation of eluxadoline
anticholinergic agents increase the effect of constipation of eluxadoline
anticholinergic agents increase the effect of constipation of eluxadoline
anticholinergic agents increase the effect of constipation of eluxadoline
may enhance the constipation effect
may enhance the constipation effect
may enhance the constipation effect
may enhance the constipation effect
may enhance the constipation effect
may increase the constipation effect of opioid agonist
may increase the constipation effect of opioid agonist
may increase the constipation effect of opioid agonist
may increase the constipation effect of opioid agonist
may increase the constipation effect of opioid agonist
opioid agonists increase the effect of constipation of eluxadoline
opioid agonists increase the effect of constipation of eluxadoline
may enhance the serum concentration
may have an increased constipating effect when combined with eluxadoline
may have an increased constipating effect when combined with eluxadoline
may have an increased constipating effect when combined with eluxadoline
may have an increased constipating effect when combined with eluxadoline
may have an increased constipating effect when combined with eluxadoline
may have an increased constipating effect when combined with eluxadoline
may have an increased constipating effect when combined with eluxadoline
may have an increased constipating effect when combined with eluxadoline
may have an increased constipating effect when combined with eluxadoline
anticholinergic agents increase the effect of constipation of eluxadoline
anticholinergic agents increase the effect of constipation of eluxadoline
anticholinergic agents increase the effect of constipation of eluxadoline
anticholinergic agents increase the effect of constipation of eluxadoline
anticholinergic agents increase the effect of constipation of eluxadoline
It may enhance the effects when combined with sufentanil by pharmacodynamic synergism
It may enhance the effect when combined with pharmacodynamic synergism
It may enhance the levels when combined with rosiglitazone by diminishing metabolism
eluxadoline: they may increase the CNS depressant effect of CNS Depressants
eluxadoline: they may increase the CNS depressant effect of CNS Depressants
eluxadoline: they may increase the CNS depressant effect of CNS Depressants
it increases the effect of constipation of anticholinergic agents
it increases the effect of constipation of anticholinergic agents
it increases the effect of constipation of anticholinergic agents
it increases the effect of constipation of anticholinergic agents
it increases the effect of constipation of anticholinergic agents
eluxadoline: they may increase the hypotensive effect of blood viscosity reducing agents
eluxadoline: they may increase the hypotensive effect of blood viscosity reducing agents
when both drugs are combined, there may be an increased level of serum concentration of alpelisib   
the level of lenvatinib increases due to a decrease in metabolism by eluxadoline
both, when used simultaneously, increases the effect of the other by synergistic activity
it may increase the constipating effect of Eluxadoline 
it may increase the constipating effect of eluxadoline 
it may increase the constipating effect of eluxadoline 
it may increase the constipating effect of eluxadoline 
may increase the metabolism of each other
may increase the constipation effect of opioid agonist
may enhance the constipating effect of opioid agonist
hydrocodone/​chlorpheniramine/​pseudoephedrineÂ
may increase the constipation activity
alosetron increases the effect of constipation of eluxadoline
opioid agonists increase the effect of constipation of eluxadoline
it decreases the effect of opioid agonists
they decrease the effect of analgesia of opioid agonists
they decrease the effect of analgesia of opioid agonists
they decrease the effect of analgesia of opioid agonists
it decreases the efficacy of opioid agonists
may increase the constipating effect of anticholinergic agents
may increase the CNS depressant effect
may increase the constipating effects of opioid agonist
may increase the constipating effect of anticholinergic agents
may increase the constipating effect of anticholinergic agents
may increase the constipating effect of Anticholinergic Agents
promethazine/dextromethorphanÂ
may increase the constipating effect of Anticholinergic Agents
may increase the constipating effect of Anticholinergic Agents
may increase the constipating effect of Opioid Agonists
methylnaltrexone: they may increase the toxic effect of mu-opioid receptor agonists
naldemedine: they may increase the toxic effect of mu-opioid receptor agonists
naloxegol: they may increase the toxic effect of mu-opioid receptor agonists
dapoxetine: they may increase the toxic effect of mu-opioid receptor agonists
may decrease the analgesic effect when combined with opioid agonists
may decrease the analgesic effect when combined with opioid agonists
may decrease the analgesic effect when combined with opioid agonists
may decrease the analgesic effect when combined with opioid agonists
The effect of either of the drugs is increased due to pharmacodynamic synergism.
OATP1B1/1B3 inhibitors increase the concentration of eluxadoline in the serum
OATP1B1/1B3 inhibitors increase the concentration of eluxadoline in the serum
OATP1B1/1B3 inhibitors increase the concentration of eluxadoline in the serum
OATP1B1/1B3 inhibitors increase the concentration of eluxadoline in the serum
OATP1B1/1B3 inhibitors increase the concentration of eluxadoline in the serum
spironolactone and hydrochlorothiazide
mu-opioid receptor agonists: they may increase the toxic effect of diuretics
mu-opioid receptor agonists: they may increase the toxic effect of diuretics
mu-opioid receptor agonists: they may increase the toxic effect of diuretics
mu-opioid receptor agonists: they may increase the toxic effect of diuretics
mu-opioid receptor agonists: they may increase the toxic effect of diuretics
mu-opioid receptor agonists: they may increase the toxic effect of loop diuretics
mu-opioid receptor agonists: they may increase the toxic effect of loop diuretics
mu-opioid receptor agonists: they may increase the toxic effect of loop diuretics
eluxadoline: they may increase the hypertensive effect of sympathomimetics
eluxadoline: they may increase the hypertensive effect of sympathomimetics
eluxadoline: they may increase the hypertensive effect of sympathomimetics
eluxadoline: they may increase the hypertensive effect of sympathomimetics
eluxadoline: they may increase the hypertensive effect of sympathomimetics
eluxadoline: they may enhance the serum concentration of CYP3A4 Inhibitors
eluxadoline: they may enhance the serum concentration of CYP3A4 Inhibitors
eluxadoline: they may enhance the serum concentration of CYP3A4 Inhibitors
eluxadoline: they may enhance the serum concentration of CYP3A4 Inhibitors
eluxadoline: they may enhance the serum concentration of CYP3A4 Inhibitors
may diminish the analgesic effect when combined with opioid agonists
may diminish the analgesic effect when combined with opioid agonists
may diminish the analgesic effect when combined with opioid agonists
may diminish the analgesic effect when combined with opioid agonists
 when thiotepa and eluxadoline combine, thiotepa increases levels of eluxadoline by affecting the enzyme cyp2b6 metabolism     
decrease the metabolism of daunorubicin and increase serum levels
the effect of eluxadoline is increased by fluorouracil by the action on CYP2C9/10 hepatic enzyme metabolism
loperamide increases the effect of constipation of eluxadoline
decrease the metabolism of idarubicin and increase serum levels
may increase the levels of each other by decreasing metabolism
they increase the effect of analgesia of opioid agonists
they increase the effect of analgesia of opioid agonists
they increase the effect of analgesia of opioid agonists
they increase the effect of analgesia of opioid agonists
they increase the effect of analgesia of opioid agonists
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
amphetamines: they may increase the analgesic effect of mu-opioid receptor agonists
anticholinestereses: they may increase the toxic effect of mu-opioid receptor agonists
anticholinestereses: they may increase the toxic effect of mu-opioid receptor agonists
anticholinestereses: they may increase the toxic effect of mu-opioid receptor agonists
anticholinestereses: they may increase the toxic effect of mu-opioid receptor agonists
anticholinestereses: they may increase the toxic effect of mu-opioid receptor agonists
desmopressin acetate: they may increase the toxic effect of mu-opioid receptor agonist
pegvisomant: they may decrease the therapeutic effect of mu-opioid receptor agonists
ramosetron: they may increase the constipating effect of mu-opioid receptor agonists
lofexidine: they may increase the toxic effect of mu-opioid receptor agonists
obinutuzumab: they may increase the toxic effect of mu-opioid receptor agonists
alfuzosin: they may increase the toxic effect of mu-opioid receptor agonists
arginine: they may increase the toxic effect of mu-opioid receptor agonists
butabarbitol: they may increase the toxic effect of mu-opioid receptor agonists
brigatinib: they may increase the toxic effect of mu-opioid receptor agonists
indoramin: they may increase the toxic effect of mu-opioid receptor agonists
loop diuretics: they may increase the toxic effect of mu-opioid receptor agonists
loop diuretics: they may increase the toxic effect of mu-opioid receptor agonists
loop diuretics: they may increase the toxic effect of mu-opioid receptor agonists
may have an increasingly adverse effect when combined with opioid agonists
Frequency defined:Â Â
1-10%Â
NauseaÂ
Urinary tract infectionsÂ
NasopharyngitisÂ
BronchitisÂ
FlatulenceÂ
Increased ALTÂ
Viral gastroenteritisÂ
Abdominal painÂ
VomitingÂ
DizzinessÂ
RashÂ
FatigueÂ
Pregnancy consideration: Studies are not performed on pregnant womenÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Patient information leafletÂ
Generic Name: EluxadolineÂ
Pronounced: (el” UX ad’ oh leen)Â
Why do we use Eluxadoline?Â
It is used to treat irritable bowel syndrome with diarrheaÂ
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
